ArticleJournal of clinical microbiology2021
A Scalable, Easy-to-Deploy Protocol for Cas13-Based Detection of SARS-CoV-2 Genetic Material.
Article in Journal of clinical microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Evaluation of CRISPR-Based Assays for Rapid Detection of SARS-CoV-2: A Systematic Review and Meta-Analysis.Yonsei medical journal · 2022Pooled it
- Accuracy of clustered regularly interspaced short palindromic repeats (CRISPR) to diagnose COVID-19, a meta-analysis.Microbial pathogenesis · 2022Pooled it
- Diagnostic efficiency of RPA/RAA integrated CRISPR-Cas technique for COVID-19: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Antibody tests for identification of current and past infection with SARS-CoV-2.The Cochrane database of systematic reviews · 2020Pooled it
- A novel Dual-guide CRISPR-Cas13 strategy improves specificity for single-nucleotide variant detection.Nucleic acids research · 2026Article
- Article
- CRISPR/Cas13-Based Anti-RNA Viral Approaches.Genes · 2025Review
- CRISPR-Cas Systems Associated with Electrolyte-Gated Graphene-Based Transistors: How They Work and How to Combine Them.Biosensors · 2024Review
- Next-generation CRISPR/Cas-based ultrasensitive diagnostic tools: current progress and prospects.RSC advances · 2024Review
- Harnessing CRISPR/Cas Systems for DNA and RNA Detection: Principles, Techniques, and Challenges.Biosensors · 2024Review
- New design strategies for ultra-specific CRISPR-Cas13a-based RNA detection with single-nucleotide mismatch sensitivity.Nucleic acids research · 2024Article
- CRISPR-Cas Technology as a Revolutionary Genome Editing tool: Mechanisms and Biomedical Applications.Iranian biomedical journal · 2023Review
- CRISPR/Cas-Based Techniques for Live-Cell Imaging and Bioanalysis.International journal of molecular sciences · 2023Review
- CRISPR/Cas13a-Based MicroRNA Detection in Tumor-Derived Extracellular Vesicles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Microbial applications for sustainable space exploration beyond low Earth orbit.NPJ microgravity · 2023Review
- The relevant information about the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using the five-question approach (when, where, what, why, and how) and its impact on the environment.Environmental science and pollution research international · 2023Review
- The SHERLOCK Platform: An Insight into Advances in Viral Disease Diagnosis.Molecular biotechnology · 2023Review
- CRISPR-Based Diagnostics and Microfluidics for COVID-19 Point-of-Care Testing: A Review of Main Applications.Molecular biotechnology · 2023Review
- Advancements in CRISPR-Based Biosensing for Next-Gen Point of Care Diagnostic Application.Biosensors · 2023Review
- Recent Advances in CRISPR-Cas Technologies for Synthetic Biology.Journal of microbiology (Seoul, Korea) · 2023Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic has created massive demand for widespread, distributed tools for detecting SARS-CoV-2 genetic material. The hurdles to scalable testing include reagent and instrument accessibility, availability of highly trained personnel, and large upfront investment. Here, we showcase an orthogonal pipeline we call CREST (Cas13-based, rugged, equitable, scalable testing) that addresses some of these hurdles. Specifically, CREST pairs commonplace and reliable biochemical methods (PCR) with low-cost instrumentation, without sacrificing detection sensitivity. By taking advantage of simple fluorescence visualizers, CREST allows a binary interpretation of results. CREST may provide a point-of-care solution to increase the distribution of COVID-19 surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.